CBS and ovarian carcinoma: Data from multiple pre‐clinical studies show that compared with adjacent normal tissues or non‐transformed cells, the expression levels of CBS in various solid tumor tissues or cell lines such as colon cancer (Phillips et al. 2017), ovarian cancer (Bhattacharyya et al. 2013), prostate cancer (Guo et al. 2012) and breast cancer (Sen et al. 2015), showed a trend of significantly higher expression levels compared with neighboring normal tissues or non‐transformed cells.